The article by Nguyen et al [1] in Journal of Clinical Oncology demonstrates an overall low local recurrence rate after breast-conserving surgery, but varying magnitude of this risk among gene expression profiling-based subtypes. The 5-year local recurrence rates of 793 patients were higher for HER-2 (8.4%) and basal (7.1%) subtypes than for luminal A (0.8%) or luminal B (1.5%) subtypes. Approximating this molecular classification using human epidermal growth factor receptor [2] (HER-2), estrogen receptor (ER), and progesterone receptor (PR) status currently used in routine clinical practice, [2] the authors provide clinically useful information on a potential link among these subtypes and local control.